Went back and listened. Never said halted. Always
Post# of 30028
Posted On: 10/06/2015 10:00:08 PM
Went back and listened. Never said halted. Always said paused and the CC was in line with the PR. I view this as good news vs. the go it alone approach. Get ODD and a partner or a grant which is the plan now. Would be interesting to know how many are enrolled right now.
Eltoprazine
Amarantus will pause enrollment for its Phase 2b clinical study of Eltoprazine due to this internal prioritization of the ESS program into multiple indications. There is no pre-clinical, safety, or other activity concern about the use of Eltoprazine that was involved in this decision. Amarantus anticipates restarting enrollment in 2016 and will evaluate various options for Eltoprazine for the treatment of Parkinson's disease Levodopa Induced Dyskinesia (PD LID). Given the recent acceptance by the FDA of PD LID as an indication eligible for the ODD pathway, the Company believes it may be able to accelerate the commercialization pathway for Eltoprazine and will use this period of enrollment pause to explore this potential . Management will accelerate the preparation of clinical development programs for Eltoprazine in Alzheimer's aggression and adult ADHD, as well as renew initiatives to obtain non-dilutive funding to accelerate program development in PD LID.
http://ir.amarantus.com/press-releases/detail...efforts-on
Eltoprazine
Amarantus will pause enrollment for its Phase 2b clinical study of Eltoprazine due to this internal prioritization of the ESS program into multiple indications. There is no pre-clinical, safety, or other activity concern about the use of Eltoprazine that was involved in this decision. Amarantus anticipates restarting enrollment in 2016 and will evaluate various options for Eltoprazine for the treatment of Parkinson's disease Levodopa Induced Dyskinesia (PD LID). Given the recent acceptance by the FDA of PD LID as an indication eligible for the ODD pathway, the Company believes it may be able to accelerate the commercialization pathway for Eltoprazine and will use this period of enrollment pause to explore this potential . Management will accelerate the preparation of clinical development programs for Eltoprazine in Alzheimer's aggression and adult ADHD, as well as renew initiatives to obtain non-dilutive funding to accelerate program development in PD LID.
http://ir.amarantus.com/press-releases/detail...efforts-on
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼